| abstract |
Adenosine analogue-type A3 receptor agonists having the formula n nwhereinn nD is N or CH;n nE is O;n nX 1 is a group of the formula —CR 20 R 2 1 -CYCLE, wheren R 20 and R 21 are the same or different and are H, F or CH 3 ; CYCLE is n n n n n n n n n n n n where G is N, CH, CF, CCH 3 or CCF 3 , n M is H, n Y is —O— or N═, and n Z is —N═ when Y is O, or is O when Y is —N═; n R 5 is H, CH 3 , I, Br, Cl, CF 3 , OH or NH 2 ; and n R 8 is —NR 9 R 10 , —CHR 9 R 10 or —N═CR 9 R 10 , where R 9 and R 10 are the same and are C 1 -C 4 alkyl, C 1 -C 4 alkenyl or C 1 -C 4 alkoxyalkyln nX 2 is mono-N— or di-N,N—(C 1 -C 4 )alkylaminocarbonyl, mono-N—or di-N,N—(C 3 -C 5 )cycloalkyl-aminocarbonyl or N-(C 1 -C 4 )alkyl-N-(C 3 -C 5 )cycloalkylamino-carbonyl;n nX 3 is OH or NH2;n nX 4 is OH;n n X 5 is H , halogen, (C 1 -C 10 )alkyl , (C 2 -C 10 )alkenyl , (C 2 -C 10 )alkynyl , or either of the latter two groups where terminally substituted by an aryl or heteroaryl group and, when having a terminal methyl group, optionally further terminally substituted by hydroxyl. The compounds may be used alone or with a pharmaceutically acceptable carrier or diluent to stimulate adenosine A 3 receptors. |